Document Detail


The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
MedLine Citation:
PMID:  20836726     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Objective. To assess the impact of metformin and of two different oral contraceptives (OCs) containing cyproterone acetate and drospirenone, on serum anti-Müllerian hormone (AMH) levels, in a cohort of women with polycystic ovary syndrome (PCOS) with hyperandrogenism. Design. Prospective randomised study. Setting. Division of Endocrinology and Human Reproduction, Aristotle University of Thessaloniki. Patients. Forty-five (45) women with PCOS diagnosed according to the criteria proposed in 1990 by the NIH. Interventions. Women with PCOS were randomised into three groups, all treated for 6 months: Group A received an OC containing 35 μg ethinylestradiol plus 2 mg cyproterone acetate, Group B received an OC containing 30 μg ethinylestradiol plus 3 mg drospirenone and Group C received metformin 850 mg × 2. Main outcome measure(s). Anti-Müllerian hormone levels were measured by a specific ELISA. Results. AMH was significantly decreased under treatment with 35 μg ethinylestradiol plus 2 mg cyproterone acetate (p = 0.002 at 3 months and p < 0.001 at 6 months). Treatment with 30 μg ethinylestradiol plus 3 mg drospirenone, and treatment with metformin 850 mg × 2 did not significantly affect serum AMH levels. AMH was significantly decreased under OCs treatment compared to metformin 850 mg × 2 (p = 0.005). Conclusion(s). AMH serum levels were significantly decreased under treatment with 35 μg ethinylestradiol plus 2 mg cyproterone acetate, due to decrease in androgens and suppression of gonadotropins.
Authors:
Dimitrios Panidis; Neoklis A Georgopoulos; Athanasia Piouka; Ilias Katsikis; Alexandros D Saltamavros; George Decavalas; Evanthia Diamanti-Kandarakis
Related Documents :
2765426 - Are fixed-dose oestrogen/progestogen combinations ideal for all hrt users?
9516036 - The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids.
2860026 - The effect of oral contraceptive formulation and field-workers: a cautionary tale.
2954886 - Efficacy of low-dose oral contraceptives containing levonorgestrel, gestoden and cyprot...
3287756 - Therapeutic efficacy of doxycycline hyclate in experimental escherichia coli infection ...
24158326 - Different volumes of injectate using electrostimulator and blinded techniques for brach...
Publication Detail:
Type:  Journal Article     Date:  2010-09-14
Journal Detail:
Title:  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology     Volume:  27     ISSN:  1473-0766     ISO Abbreviation:  Gynecol. Endocrinol.     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8807913     Medline TA:  Gynecol Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1-6     Citation Subset:  IM    
Affiliation:
Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral ...
Next Document:  Relation between C-reactive protein and body mass index in patients with polycystic ovarian syndrome...